Introduction
Protease inhibitors were designed specifically to inhibit HIV protease, yet serendipitously have been found to have broad antineoplastic and antiviral activity [1, 2] . In particular, nelfinavir exhibits anticancer properties (e.g. inhibition of Akt signalling, induction of cancer cell autophagy and apoptosis, proteasome inhibition) against a range of cancers including myeloma, breast cancer, ovarian cancer, liposarcoma, melanoma, nonsmall cell lung cancer, diffuse large B-cell lymphoma, glioma, hepatocellular carcinoma, and prostate cancer [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . It has also been shown to suppress Kaposi's sarcomaassociated herpesvirus replication in vitro [16] . Since the approval of nelfinavir as an antiretroviral in 1997, more efficacious alternatives with fewer adverse effects have taken over the role of protease inhibitors in antiretroviral therapy (ART). However, clinical trials are currently being undertaken to investigate whether nelfinavir could be repositioned as an anticancer agent [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] .
All ART, by increasing CD4 cell count, substantially reduces the risk of AIDS and non-AIDS-defining cancer in HIV-positive individuals [27] [28] [29] . Portsmouth et al. reported that the incidence of Kaposi's sarcoma in the HIV-positive population decreased from 30/1000 person-years before 1995 (the pre-ART era) to 0.03/1000 person-years in 2001 and that nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART had a similar protective effect to protease inhibitor-based ART [29] . However, the relative efficacy of nelfinavirbased ART compared with other ART in preventing cancer has only been clinically evaluated in one small study of HIV-positive individuals which found no difference between regimens [30] . The potentially protective effect of nelfinavir against Kaposi's sarcoma and other specific cancers has not been assessed in any HIV cohort.
In June 2007, Viracept (nelfinavir mesylate) was subject to an international recall because of a manufacturing fault that led to the product containing high levels of ethyl mesylate, a genotoxic substance that has been associated with increased rates of lung, kidney, brain, liver, breast, and uterine cancer in animal models [31] . The contamination arose from Roche's manufacturing plant in Switzerland. All nelfinavir users living outside of the USA, Canada, and Japan (where nelfinavir supplies were not manufactured by Roche) at the time were considered to be at risk of exposure. In the worst case scenario, up to 25 000 people may have consumed contaminated nelfinavir between late 2006 and early 2007. The most severely contaminated batches were distributed between March 2007 and June 2007 and individuals may have taken highly contaminated nelfinavir for up to 3 months [32] [33] [34] . Following a review of toxicology studies [31, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] , the European Medicines Agency concluded that the contamination did not increase the risk of 1630 AIDS 2016, Vol 30 No 10 developing cancer and that further follow-up of affected individuals was not required [33] . Nevertheless, longterm clinical data supporting this decision have not been reported.
The objective of this analysis was to evaluate the potential of nelfinavir as a cancer preventive in HIV-positive persons enrolled in a very large cohort study, and to assess the rates of cancer in individuals exposed to nelfinavir between late 2006 and early 2007.
Methods
The Data collection on Adverse events of Anti-HIV drugs (D:A:D) Study has been described in detail elsewhere [46] [47] [48] [49] . Briefly, it is a prospective study formed by the collaboration of 11 cohorts in Europe, Australia, and the United States. All participating cohorts in D:A:D followed local national guidelines/regulations regarding patient consent and/or ethical review. Information on all AIDS events, including all new AIDS-defining cancers (Kaposi's sarcoma, non-Hodgkin's lymphoma, and cervical cancer), has been provided prospectively on an annual basis since the start of the study in 1999. Since 2008, information has also been collected on non-AIDS-defining cancers (other than basal or squamous cell skin cancer, precancers, and relapses). All participating cohorts have been collecting information prospectively on non-AIDS-defining cancers from 2008 or earlier; information was also collected retrospectively on events occurring between 1 January 2004 and 31 January 2008. Detailed information on each cancer is collected on a specific case report form. All reported events are validated centrally at the D:A:D coordinating centre with a proportion of events selected for discussion with an external consultant oncologist. All events are regularly monitored for accuracy, and random monitoring is performed at participating centres to ensure complete ascertainment of events. D:A:D participants were followed from the latest of 1 January 2004 or D:A:D study entry (baseline), until the earliest of a first incident cancer diagnosis, 1 February 2014, death, or 6 months after the last visit. As in previous analyses of the data set, each individual's follow-up was split into a series of consecutive 1 month periods and his/her age and clinical status (including ART use) at the start of each period was established. At the time of study entry, individuals may have already been exposed to ART, with exposure then accruing over follow-up.
End points
We performed analyses on all cancer, AIDS-defining cancer, non-AIDS-defining cancer, and noninfectionrelated cancer diagnoses. Noninfection-related cancers were considered those not normally associated with an infectious agent. These included multiple myeloma, leukemia, melanoma, and cancers of the lung, brain, kidney, testes, breast, colon, rectum, prostate, bladder, bone, body of uterus, lip, pancreas, gall bladder, oesophagus, or connective tissue. Some cancer codes in the D:A:D database cannot be clearly identified as noninfection-related (e.g. head and neck cancer) and were therefore not included in this list. This was because the aim of investigating noninfection-related cancers was to assess the anticancer potential of nelfinavir where restoration of immune function was less protective. Several of the more frequently occurring cancer types were also considered separately (non-Hodgkin's lymphoma, Kaposi's sarcoma, lung cancer, and anal cancer). In each analysis, follow-up of participants diagnosed with a cancer other than the one of interest was right censored at the time of cancer diagnosis to avoid any bias that might be introduced through more frequent subsequent monitoring for cancer.
Statistical analysis
Poisson regression models were used to assess associations between the incidence of cancer and: cumulative exposure to nelfinavir; current exposure to nelfinavir; and exposure to nelfinavir between 1 July 2006 and 30 June 2007 (defined as the risk period for exposure to contaminated nelfinavir). A patient's cumulative exposure to therapy at the start of each 1 month follow-up period was calculated (including the duration of treatment before D:A:D enrollment and during follow-up) and the result used to assign the patient-month (and any endpoint events that occurred during that month) to the appropriate exposure category. Patients were considered to be currently using a regimen when it was their prescribed ARTat the beginning of a patient-month. The effect of nelfinavir exposure between 1 July 2006 and 30 June 2007 and cancer incidence was only evaluated amongst individuals who had contributed some followup time on ART over that period so as to limit the influence of calendar year and different ART use on our results. We were not able to specifically identify individuals that were exposed to contaminated nelfinavir. Treatment covariates were time-updated, so an individual's treatment status could change over time; reported adjusted rate ratio (aRR) estimates for cumulative ART exposure were scaled to reflect the impact of each additional 5 years of ART exposure on the outcome thereby enhancing their clinical relevance. Each model compared exposure to ART regimens (categorized as: nelfinavir-based-ART; nonnelfinavir, protease inhibitorbased ART; NNRTI-based ART; other ART; and no ART), either as cumulative exposure or current exposure. Models were additionally adjusted for sex, mode of HIV acquisition, cancer diagnosis prior to baseline (all as fixed covariates), age (as a continuous, time-updated covariate), hepatitis B surface antigen status and hepatitis C antibody status (as time-updated covariates). All analyses were performed using SAS, version 9.3 (SAS Institute Inc., Cary, North Carolina, USA).
Sensitivity analyses
Because of the potential role of CD4 cell count and HIV viral load as confounders for initiation of ART and factors on the causal pathway between the initiation of ART and cancer development, our primary analyses did not include adjustment for these variables. Interpretation of rate ratios is impeded by the selection bias introduced in such analyses [50] . Nevertheless, sensitivity analyses considered whether our conclusions regarding cumulative and current nelfinavir use were modified by adjusting for the latest (time updated) CD4 þ cell count and HIV-RNA level. We also investigated the effect of adjusting for calendar year.
Results
A total of 42 006 participants (from the nine D:A:D cohorts that provide data on both AIDS and non-AIDS-defining cancers) were included, accounting for 303 005 personyears of follow-up. Participant characteristics are described in Table 1 
Association between cancer incidence and cumulative nelfinavir exposure
The incidences of each type of cancer stratified by cumulative exposure to different types of ART are shown in Table, Supplemental Digital Content 1, http:// links.lww.com/QAD/A884. Table 2 , http://links.lww. com/QAD/A884 shows the adjusted associations between increasing cumulative exposure to ART (per additional five years) and the eight cancer categories/ cancers analysed. Greater cumulative exposure to nelfinavir was not associated with a significant change in overall cancer incidence but was associated with an elevated risk of non-AIDS-defining cancer (aRR 1.19 per additional 5 years, 95% CI 1.03-1.37, P ¼ 0.02). All regimens, including nelfinavir-based ART, were associated with a significant reduction in AIDS-defining cancer, non-Hodgkin's lymphoma, and Kaposi's sarcoma (see Table 2 ). Although increased exposure to nonnelfinavir, protease inhibitor-ART was associated with a higher risk of anal cancer (aRR 1.40 per additional 5 years, 95% CI 1.16-1.71, P < 0.01), no such association was found for nelfinavir-based ART. Rates of noninfection-related cancer and lung cancer were unchanged by greater exposure to any category of ART.
Association between cancer incidence and current nelfinavir exposure
The incidences of each type of cancer stratified by current exposure to different types of ART are shown in Table, Supplemental Digital Content 2, http://links.lww.com/ QAD/A884. The adjusted associations between current ART exposure and cancer incidences are shown in Table  3 . Rates of cancer were nonsignificantly different between individuals receiving nelfinavir-based treatment and other protease inhibitor-based ART. The incidences of noninfection-related cancer and lung cancer were not associated with current ART regimen. However, rates of all cancer, AIDS-defining cancer, non-AIDS-defining cancer, non-Hodgkin's lymphoma, Kaposi's sarcoma, and anal cancer were lower in individuals using NNRTIbased ART compared with those using nonnelfinavir, protease inhibitor-ART (see Table 3 ). Not using ARTwas associated with a significantly higher risk of all cancer, AIDS-defining cancer, non-Hodgkin's lymphoma, and Kaposi's sarcoma, and a lower risk of non-AIDS-defining cancer and anal cancer (see Table 3 ). Figure 1 shows the incidences of all, AIDS-defining, non-AIDS-defining, and noninfection-related cancers were similar amongst individuals exposed to nelfinavir in the risk period and other nelfinavir users. These comparisons remained similar when adjusted for important demographic and lifestyle variables and hepatitis status (as described in the Methods section; Table 4 ).
Sensitivity analyses
Our conclusions regarding the association between nelfinavir exposure and cancer incidence were unchanged in cumulative and current exposure models that additionally adjusted for the latest CD4 þ cell cell count and HIV-RNA level, or for calendar year (results not shown).
Discussion
Despite strong evidence that nelfinavir exhibits potent anticancer properties [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , the only association we found between nelfinavir exposure (both increasing cumulative exposure and current exposure versus no ART) and reduced cancer incidence occurred with AIDS-defining cancers and is most likely explained by ART-induced immune reconstitution [51] [52] [53] [54] [55] . We did not observe a specific cancer protective effect of nelfinavir use over and above that seen for other protease inhibitors.
Additionally, our results indicate that the 2006/2007
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In an analysis of 2499 HIV-positive people enrolled in a US cohort, a similar relationship between nelfinavir use and cancer incidence was found [30] . Although the authors suggested that their results may have been related to the need for a larger cohort to detect a specific protective effect of nelfinavir, our findings show that this is probably not the case. It cannot be ruled out, however, that a study of longer follow-up duration could reveal an association between nelfinavir use and the incidence of slow-progressing cancers. An alternative explanation might be that nelfinavir at doses used for HIV suppression are insufficient for cancer prevention. Interestingly, the maximum-tolerated dose of nelfinavir was not determined during initial development. Clinical trials evaluating the efficacy of high dose nelfinavir in cancer treatment will soon provide further insight into optimal oncological dosing [17, 19, 25] .
Protease inhibitors induce apoptosis and inhibit nuclear factor kB in Kaposi's sarcoma cell lines [56] , and also exhibit a host of anticancer properties in other cancer types [2] . Despite the fact that only nelfinavir displays inhibitory activity against Kaposi's sarcoma-associated herpesvirus [16] , we found that nelfinavir use had a similar effect on Kaposi's sarcoma incidence to other protease inhibitor-based ART. Importantly, insufficient dosing is unlikely to explain this result as nelfinavir is active against Kaposi's sarcoma-associated herpesvirus at in-vitro concentrations similar to those achieved in plasma with dosing used to treat HIV [16] .
Consistent with an earlier D:A:D analysis [27] , we found cumulative and current exposure to NNRTI-based ART was associated with a lower risk of both AIDS and non-AIDS-defining cancers compared with protease inhibitor-based ART. Further discussion of these findings can be found in the original paper although the mechanism behind this observation remains unclear and does not appear to be associated with different rates of immune recovery with NNRTIs and protease inhibitors [27] . Adding to this dialogue, we found cumulative exposure to nelfinavir-based ART appears to partially drive the positive association between protease inhibitorexposure and non-AIDS-defining cancer. However, the difference in cancer risk between NNRTI and protease inhibitor-based ART did not extend to noninfectionrelated cancers. Interestingly, the risk of both non-AIDS-defining cancer and anal cancer was lower in patients not currently using ART when compared with patients using a nonnelfinavir, protease inhibitor-based regimen. The effect size of these associations were similar to those seen with NNRTI-based ART which suggests the increased risk of non-AIDS-defining cancer with protease inhibitor-based ART compared to NNRTIbased ART may be related to an increased rate of cancer with protease inhibitor exposure rather than a lower rate of cancer with NNRTI use.
The global recall of nelfinavir in June 2007 prompted a series of studies to investigate the extent of DNA damage induced by high doses of ethyl mesylate and the likely impact on cancer occurrence in humans. Animal studies were undertaken to establish a threshold dose beyond which DNA damage begins to accumulate [36, 37, 57] . This was estimated at 25 mg/kg per day. Following extrapolation of these data to humans, it was shown that even at an exposure 30 to 370-fold higher than that ingested by nelfinavir users (estimated at 0.055 mg/kg per day in the worst case scenario), the chromosomal damage incurred would still be effectively managed by cellular DNA repair mechanisms [40] [41] [42] . The European Medicines Agency was satisfied by this body of work and concluded that further follow-up of affected individuals was not required [33] . Although we were unable to specifically identify individuals exposed to contaminated nelfinavir in our analysis, our results provide the first clinical evidence supporting the abovementioned toxicology studies. As the aRRs reported are very close to one, it seems unlikely these results would be altered by a larger study. However, it cannot be discounted that a study with a maximum follow-up time greater than 7.5 years after contaminated nelfinavir exposure might reveal different results to ours.
As most cancer diagnoses result in hospitalization, information on which is generally passed back to D:A:D cohorts, we do not believe the cancer rates reported here are underestimated. Nevertheless, there were several limitations to this study that have not been mentioned above. Numerous factors may affect cancer risk, yet, to avoid overfitting our models, we only adjusted for age, gender, mode of HIV acquisition, hepatitis B surface antigen status, hepatitis C antibody status and history of cancer. The possibility that other potential confounding factors influenced our analysis cannot be ruled out. We were also hindered by low event numbers for many cancer types. This prevented analysis of a number of specific cancers and meant we could not look at any individual cancer types in our analysis of persons exposed to nelfinavir between 1 July 2006 and 30 June 2007.
Nelfinavir use was not associated with reduced cancer incidence compared to other protease inhibitor-based ART regimens. As of February 2014, exposure to the 2006/2007 contamination of nelfinavir does not appear to be associated with increased cancer incidence. 
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